News
Public · Published
Oppenheimer reiterates Outperform rating on Agilysys, $135 price target
Oppenheimer reiterated an Outperform rating on Agilysys stock with a $135.00 price target, implying 9.4% upside from the October 26 close of $123.45. The analyst note cited second-quarter results above consensus estimates for total revenue and adjusted EBITDA, with subscription revenue growth accelerating to 33%.
Published:
Updated:
What happened
Oppenheimer reiterated an Outperform rating on Agilysys stock with a $135.00 price target, implying 9.4% upside from the October 26 close of $123.45. The analyst note cited second-quarter results above consensus estimates for total revenue and adjusted EBITDA, with subscription revenue growth accelerating to 33%.
Confirmed
Global impact / market context
An Outperform rating means the analyst expects the stock to beat the broader market. The higher target suggests Oppenheimer sees more value ahead, supported by accelerating subscription revenue and raised guidance, which may reassure investors about future earnings growth in hospitality software.
Analyst inference
Agilysys sells software to hospitality businesses, so recurring subscription revenue matters for steady cash flow. Management raised full-year revenue and adjusted EBITDA margin guidance, which means expected profit per sale improved, signaling stronger core performance and confidence in the Marriott project despite the stock trading below the new target.
Analyst inference
What to watch
- Agilysys raised its full-year revenue and adjusted EBITDA margin guidance, so watch whether upcoming quarterly results deliver revenue and profit per sale consistent with that raised outlook. Confirmed
- Oppenheimer's $135.00 target implies 9.4% upside from the $123.45 close; track whether the share price moves toward that level as subscription growth and Marriott project progress unfold. Proposed
- Subscription revenue growth accelerated to 33%, so watch whether that pace holds; slower growth could pressure the earnings potential Oppenheimer cited when reiterating its Outperform rating. Analyst inference
Evidence
- Original source link unavailable